目的检验汉密顿抑郁量表6项版本（HAMD-6）的信度与效度。
Objective To explore the validity and reliability of the 6-item Hamilton Depression Rating Scale (HAMD-6).
汉密顿抑郁量表分数的降低支持了临床治疗，平均差别在2.26个百分点。
The average reduction in HAM-D scores favored clinical management, at an average difference of 2.26 points.
在12周的治疗期间，西酞普兰被证明要好于安慰剂，在汉密顿抑郁量表的得分上要比其低3.3个百分点。
Over the 12 weeks of treatment, citalopram proved to be superior to placebo, with an average 3.3-point greater reduction in HAM-D scores.
采用汉密顿抑郁量表（HAMD）、抑郁自评量表（SDS）、SF - 36、类风关生命质量量表在治疗前后作评定。
The quality of life in patients with rheumatoid arthritis at the entry study and end study were evaluated by HAMD, SDS, SF-36 respectively.
方法对16例脑卒中伴语言障碍患者通过卡通卡片、体态语言等方法改善沟通，在入院时、入院后1周、入院后2周分别用汉密顿抑郁量表评定患者抑郁程度。
Methods16 patients with stroke dysphasia communicated with carton CARDS, body signal. All the patients were assessed by Hamilton Depression Scale (HAMD) in admission day, one week and two weeks later.
反应率，定义为在汉密顿抑郁量表的得分上有50%或者更多的减少，要高于那些接受西酞普兰治疗的病人，其结果是35.9%比上22.5%，对于那些给予安慰剂的病人来说。
The response rate, defined as a 50% or greater reduction in HAM-D scores, was higher among patients receiving citalopram, at 35.9% compared with 22.5% for those given placebo.
反应率，定义为在汉密顿抑郁量表的得分上有50%或者更多的减少，要高于那些接受西酞普兰治疗的病人，其结果是35.9%比上22.5%，对于那些给予安慰剂的病人来说。
The response rate, defined as a 50% or greater reduction in HAM-D scores, was higher among patients receiving citalopram, at 35.9% compared with 22.5% for those given placebo.
应用推荐